535 related articles for article (PubMed ID: 32760015)
1. ROS1-dependent cancers - biology, diagnostics and therapeutics.
Drilon A; Jenkins C; Iyer S; Schoenfeld A; Keddy C; Davare MA
Nat Rev Clin Oncol; 2021 Jan; 18(1):35-55. PubMed ID: 32760015
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Targeting ROS1 in Lung Cancer.
Lin JJ; Shaw AT
J Thorac Oncol; 2017 Nov; 12(11):1611-1625. PubMed ID: 28818606
[TBL] [Abstract][Full Text] [Related]
3. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Neel DS; Allegakoen DV; Olivas V; Mayekar MK; Hemmati G; Chatterjee N; Blakely CM; McCoach CE; Rotow JK; Le A; Karachaliou N; Rosell R; Riess JW; Nichols R; Doebele RC; Bivona TG
Cancer Res; 2019 Feb; 79(3):546-556. PubMed ID: 30538120
[TBL] [Abstract][Full Text] [Related]
4. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
6. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
7. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
8. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
9. Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.
Li S; Zhang H; Chen T; Zhang X; Shang G
Cancer Med; 2024 Apr; 13(8):e7201. PubMed ID: 38629293
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
14. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
15. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
16. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.
Ogura H; Nagatake-Kobayashi Y; Adachi J; Tomonaga T; Fujita N; Katayama R
Sci Rep; 2017 Jul; 7(1):5519. PubMed ID: 28717217
[TBL] [Abstract][Full Text] [Related]
17. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
18. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
20. ROS1-rearranged Non-small Cell Lung Cancer.
Giustini NP; Bazhenova L
Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]